CA2251987A1 - Microparticles - Google Patents

Microparticles

Info

Publication number
CA2251987A1
CA2251987A1 CA002251987A CA2251987A CA2251987A1 CA 2251987 A1 CA2251987 A1 CA 2251987A1 CA 002251987 A CA002251987 A CA 002251987A CA 2251987 A CA2251987 A CA 2251987A CA 2251987 A1 CA2251987 A1 CA 2251987A1
Authority
CA
Canada
Prior art keywords
particles
microparticles
organic solvent
solvent system
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002251987A
Other languages
French (fr)
Other versions
CA2251987C (en
Inventor
Michael E. Rickey
J. Michael Ramstack
Danny H. Lewis
Jean Louis Mesens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Alkermes Controlled Therapeutics Inc II
Original Assignee
Alkermes Controlled Therapeutics Inc. Ii
Janssen Pharmaceutica N.V.
Michael E. Rickey
J. Michael Ramstack
Danny H. Lewis
Jean Louis Mesens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21917114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2251987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkermes Controlled Therapeutics Inc. Ii, Janssen Pharmaceutica N.V., Michael E. Rickey, J. Michael Ramstack, Danny H. Lewis, Jean Louis Mesens filed Critical Alkermes Controlled Therapeutics Inc. Ii
Publication of CA2251987A1 publication Critical patent/CA2251987A1/en
Application granted granted Critical
Publication of CA2251987C publication Critical patent/CA2251987C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/04—Making microcapsules or microballoons by physical processes, e.g. drying, spraying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Abstract

The invention provides a process for the preparation of biodegradable biocompatible microparticles, said process comprising:
contacting microparticles comprising a biodegradable biocompatible polymer matrix containing an active (e.g. pharmaceutical or diagnostic) agent and an organic solvent with an aqueous solvent system whereby the content of said organic solvent in said particles is reduced to 2 %
or less of the weight of said particles said solvent system being such as to satisfy at least one of the conditions (a) that it is at an elevated temperature (e.g. from 25 to 40 °C) during at least pan of the time that it is in contact with said particles, and (b) that it comprises water and water-miscible solvent for said organic solvent; and recovering said particles from said aqueous solvent system.
CA002251987A 1996-05-07 1997-05-06 Microparticles Expired - Lifetime CA2251987C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4155196P 1996-05-07 1996-05-07
US60/041,551 1996-05-07
PCT/EP1997/002431 WO1997041837A2 (en) 1996-05-07 1997-05-06 Microparticles

Publications (2)

Publication Number Publication Date
CA2251987A1 true CA2251987A1 (en) 1997-11-13
CA2251987C CA2251987C (en) 2005-05-10

Family

ID=21917114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251987A Expired - Lifetime CA2251987C (en) 1996-05-07 1997-05-06 Microparticles

Country Status (23)

Country Link
US (9) US5792477A (en)
EP (1) EP0904063B1 (en)
JP (2) JP3822909B2 (en)
KR (1) KR100432677B1 (en)
CN (1) CN1224380C (en)
AR (2) AR012820A1 (en)
AU (1) AU733199B2 (en)
BG (1) BG64036B1 (en)
BR (1) BR9709217A (en)
CA (1) CA2251987C (en)
CZ (1) CZ293578B6 (en)
EE (1) EE04540B1 (en)
HU (1) HU223532B1 (en)
ID (1) ID17505A (en)
IL (1) IL126509A (en)
NO (2) NO323591B1 (en)
NZ (1) NZ333196A (en)
PL (1) PL188550B1 (en)
RU (1) RU2201214C2 (en)
SK (1) SK283852B6 (en)
UA (1) UA59361C2 (en)
WO (1) WO1997041837A2 (en)
ZA (1) ZA973891B (en)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354270B1 (en) * 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazole and 1,2-benzisothiazole
DE19545257A1 (en) 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
UA72189C2 (en) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
ATE313319T1 (en) * 1999-03-31 2006-01-15 Janssen Pharmaceutica Nv PREGELATINATED STARCH IN A CONTROLLED RELEASE FORMULATION
EP1044683A1 (en) * 1999-04-15 2000-10-18 Debio Recherche Pharmaceutique S.A. One-step dispersion method for the microencapsulation of water soluble substances
US6291013B1 (en) 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US7030097B1 (en) 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
FR2797784B1 (en) * 1999-08-27 2001-11-30 Mainelab PROCESS FOR THE ENCAPSULATION OF ACTIVE MATERIALS BY COACERVATION OF POLYMERS IN NON-CHLORINE ORGANIC SOLVENT
ES2162746B1 (en) * 1999-10-21 2003-02-16 Lipotec Sa MICROCAPSULES FOR THE STABILIZATION OF COSMETIC, PHARMACEUTICAL OR FOOD PRODUCTS.
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
GB2356386A (en) 1999-11-17 2001-05-23 Tagra Biotechnologies Ltd Microencapsulation
US7838037B2 (en) * 1999-11-17 2010-11-23 Tagra Biotechnologies Ltd. Method of microencapsulation
ATE326222T1 (en) 2000-03-15 2006-06-15 Wolfgang Sadee NALOXONE AND NALTREXONE ANALOGUES IN DRUG ABUSE TREATMENT
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
KR100902625B1 (en) * 2000-08-15 2009-06-15 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Microparticles
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) * 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
AU9445801A (en) * 2000-10-06 2002-04-15 Bioglan Ab Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight
SE517421C2 (en) 2000-10-06 2002-06-04 Bioglan Ab New production of microparticles involves use of aqueous solution of purified amylopectin-based starch of reduced molecular weight
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
ES2382636T3 (en) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Method for producing compositions for improved administration of bioactive molecules
ES2292634T3 (en) 2000-12-21 2008-03-16 Alrise Biosystems Gmbh Induced phase transition procedure for the production of microparticles containing active hydrophilic agents.
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
WO2002058671A1 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Burst free pharmaceutical microparticules
EP1372729B1 (en) * 2001-02-23 2009-04-08 Genentech, Inc. Erodible polymers for injection
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
WO2003002100A1 (en) * 2001-06-26 2003-01-09 Farrell John J Tamper-proof narcotic delivery system
MXPA04002446A (en) 2001-09-26 2004-07-23 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
DK1455593T3 (en) 2001-10-06 2013-08-26 Merial Ltd PROCEDURES AND COMPOSITIONS FOR PROMOTING GROWTH AND INJURY IMMUNITY OF YOUNG ANIMALS
SE0201599D0 (en) * 2002-03-21 2002-05-30 Skyepharma Ab microparticles
US7160551B2 (en) * 2002-07-09 2007-01-09 The Board Of Trustees Of The University Of Illinois Injectable system for controlled drug delivery
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
NZ537955A (en) * 2002-07-31 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7736391B2 (en) 2003-02-06 2010-06-15 Tonaba Healthscience Ii, Llc Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis
US6908484B2 (en) * 2003-03-06 2005-06-21 Spinecore, Inc. Cervical disc replacement
WO2004108792A2 (en) * 2003-04-10 2004-12-16 Vinod Chintamani Malshe Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US8916196B2 (en) 2003-04-10 2014-12-23 Evonik Corporation Method for the production of emulsion-based microparticles
WO2004108115A1 (en) * 2003-06-03 2004-12-16 Santen Pharmaceutical Co., Ltd. Process for producing microparticle
JP2007526217A (en) * 2003-06-04 2007-09-13 アルカーメス，インコーポレイテッド Polymorphic form of naltrexone
CA2533314C (en) 2003-07-18 2013-07-09 Oakwood Laboratories, L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
CA2533592C (en) 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2005015160A2 (en) * 2003-08-07 2005-02-17 The Children's Hospital Of Philadelphia Functionalized polymeric colloids
US7309500B2 (en) * 2003-12-04 2007-12-18 The Board Of Trustees Of The University Of Illinois Microparticles
EP2633853A1 (en) * 2004-01-12 2013-09-04 The Trustees of The University of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2552758A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
CA2552757A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
US20050245541A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US20050245461A1 (en) * 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
US8617613B2 (en) 2004-04-15 2013-12-31 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7919499B2 (en) 2004-04-22 2011-04-05 Alkermes, Inc. Naltrexone long acting formulations and methods of use
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
US7748343B2 (en) 2004-11-22 2010-07-06 The Board Of Trustees Of The University Of Illinois Electrohydrodynamic spraying system
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
WO2006078841A1 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
US7608612B2 (en) * 2005-01-21 2009-10-27 Richard H. Matthews Radiosensitizer formulations and methods for use
US8598092B2 (en) 2005-02-02 2013-12-03 Halliburton Energy Services, Inc. Methods of preparing degradable materials and methods of use in subterranean formations
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101283946B1 (en) * 2005-07-18 2013-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Drug-containing implants and methods of use thereof
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
BRPI0620268B8 (en) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC effective composition as a delivery system for controlled release, its use, its method of manufacture, and method of protecting a biologically active agent
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
EP2012803A4 (en) * 2006-04-20 2012-08-01 Univ Utah Res Found Polymeric compositions and methods of making and using thereof
KR100781604B1 (en) * 2006-06-13 2007-12-03 한불화장품주식회사 Method of stabilization of active ingredients that have low solubility, using hollow type multi-layered microcapsule made of hydrophobic polymer/polyhydric alcohols and preparation method thereof, and cosmetic composition containing the microcapsules
CN102274557B (en) 2006-08-09 2014-12-03 精达制药公司 Osmotic delivery systems and piston assemblies
ES2420479T3 (en) * 2006-08-31 2013-08-23 Sk Chemicals, Co., Ltd. Procedure for the production of microspheres loaded with drugs and microspheres loaded with drugs produced therewith
US20090263346A1 (en) * 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
US20100210792A1 (en) * 2006-12-05 2010-08-19 David Taft Drug delivery
EP2129757A2 (en) * 2007-01-11 2009-12-09 Novozymes A/S Particles comprising active compounds
CA2680365A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
DK2157967T3 (en) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and applications thereof
WO2008153611A2 (en) 2007-05-25 2008-12-18 Qlt Usa, Inc. Sustained delivery formulations of risperidone compounds
WO2008157540A1 (en) * 2007-06-20 2008-12-24 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
JP2011500686A (en) 2007-10-18 2011-01-06 アイコ バイオテクノロジー Combined analgesics using opioids and neutral antagonists
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20110027361A1 (en) * 2008-02-04 2011-02-03 Torrent Pharmaceuticals Ltd. Extended release dosage form of paliperidone
CN102231981A (en) * 2008-02-08 2011-11-02 昌达生物科技公司 Composition for sustained release delivery of proteins or peptides
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX2010014018A (en) 2008-06-16 2011-06-21 Bind Biosciences Inc Drug loaded polymeric nanoparticles and methods of making and using same.
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8318211B2 (en) * 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
JP5757872B2 (en) * 2008-09-11 2015-08-05 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ Solvent extraction microencapsulation with adjustable extraction rate
EP2334288B1 (en) * 2008-09-18 2021-05-19 Evonik Corporation Microencapsulation process with solvent and salt
CN102209531B (en) * 2008-11-14 2014-08-27 梨花女子大学校产学协力团 Method for preparing microspheres and microspheres produced thereby
US20100143479A1 (en) * 2008-12-04 2010-06-10 Oakwood Laboratories, Llc Method of making sustained release microparticles
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (en) 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
ES2319158B1 (en) * 2008-12-23 2010-01-26 Grifols, S.A COMPOSITION OF BIOCOMPATIBLE ALGINIC ACID MICROPARTICLES FOR THE CONTROLLED RELEASE OF ACTIVE PRINCIPLES BY INTRAVENOUS VIA.
JP2012515790A (en) * 2009-01-23 2012-07-12 サーモディクス ファーマシューティカルズ， インコーポレイテッド Continuous double emulsion process for fine particle production
US20100196436A1 (en) * 2009-01-30 2010-08-05 Gooberman Lance L Implants containing disulfiram and an anti-inflammatory agent
US8791093B2 (en) * 2009-05-29 2014-07-29 Lance L. Gooberman Pharmaceutical delivery systems for treatment of substance abuse and other addictions
LT2462246T (en) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
EA036522B1 (en) 2009-12-11 2020-11-19 Пфайзер Инк. Pharmaceutical composition suitable for lyophilization comprising a plurality of therapeutic particles
JP5965844B2 (en) 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド Therapeutic polymer nanoparticle compositions having high glass transition temperature or high molecular weight copolymers
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
AU2011250934B2 (en) 2010-05-11 2016-02-25 Howmedica Osteonics Corp., Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
KR20120011344A (en) * 2010-07-21 2012-02-08 에스케이케미칼주식회사 Method for preparing microspheres and microspheres produced thereby
US20120082731A1 (en) * 2010-09-30 2012-04-05 Adrian Raiche Method For Removing Residual Organic Solvent From Microparticles
CA2813302A1 (en) * 2010-09-30 2012-04-05 Evonik Corporation Emulsion method for preparing low residual solvent microparticles
EP3257498B1 (en) * 2010-12-29 2019-04-24 Medincell Biodegradable drug delivery compositions
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012158527A2 (en) 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
KR101481859B1 (en) * 2011-05-20 2015-01-14 에스케이케미칼주식회사 Method for preparing microparticles with reduced initial drug release and microparticles prepare thereby
KR101265955B1 (en) 2011-09-07 2013-05-22 한불화장품주식회사 Cosmetic composition using microcapsules containing fermented herb medicine extracts
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
CN103834054B (en) * 2012-11-27 2018-05-11 东丽先端材料研究开发（中国）有限公司 The preparation method of polylactic acid hollow microsphere
HRP20171402T4 (en) 2013-06-20 2023-07-21 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
FI3010962T4 (en) * 2013-06-20 2023-05-04 Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
WO2015020240A1 (en) 2013-08-06 2015-02-12 동국제약 주식회사 Entecavir microspheres and pharmaceutical composition for parenteral administration containing same
JP6505705B2 (en) * 2013-12-05 2019-04-24 アルライズ バイオシステムズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for producing a preparation for oral administration
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
HUE043964T2 (en) 2014-03-14 2019-09-30 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
US9439864B2 (en) * 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
KR101738127B1 (en) 2014-08-08 2017-05-22 (주)비씨월드제약 A method for producing drug-containing sustained release micro particle
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016071767A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Buprenorphine dosing regimens
CN113598842A (en) 2015-06-03 2021-11-05 因塔西亚制药公司 Implant placement and removal system
CA2987081C (en) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
US20200155449A1 (en) 2015-11-16 2020-05-21 Medincell Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN109718209B (en) * 2017-10-30 2021-03-05 浙江圣兆药物科技股份有限公司 Freeze-drying method of risperidone microspheres with low ethanol residues
CN109718212A (en) * 2017-10-30 2019-05-07 浙江圣兆药物科技股份有限公司 A method of reducing low solvent flashing benzyl alcohol in Risperidone microballoon
KR101862197B1 (en) * 2018-02-02 2018-05-29 이상운 Guide panel fixing apparatus having rain-water ponding preventing structure
CN111714442B (en) * 2019-03-04 2024-04-12 广州铂思雅生物医药科技有限公司 Preparation of the implant
GR1009870B (en) * 2019-07-09 2020-11-12 Φαρματεν Α.Β.Ε.Ε. Pharaceutical composition comprising an atypical antipsychotic drug and method for the preparation thereof
CN110407652B (en) * 2019-08-19 2021-02-02 安徽雷鸣科化有限责任公司 Mixed loading equipment for water gel explosive and control method thereof
CN113116830A (en) * 2019-12-31 2021-07-16 广州铂思雅生物医药科技有限公司 Preparation of sustained-release granules
WO2021199077A1 (en) 2020-03-30 2021-10-07 Biological E Limited Risperidone microspheres, process for their prepartion and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL137652C (en) * 1962-07-11
BE744162A (en) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd ENCAPSULATION PROCESS
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (en) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
JPS523342B2 (en) * 1972-01-26 1977-01-27
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
JPS523653A (en) * 1975-06-27 1977-01-12 Fuji Photo Film Co Ltd Process for producing fine polymer particles
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
WO1989003678A1 (en) * 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
DE8812411U1 (en) 1988-09-29 1990-02-08 Siemens Ag, 1000 Berlin Und 8000 Muenchen, De
IL92344A0 (en) * 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
ATE133087T1 (en) * 1989-05-04 1996-02-15 Southern Res Inst ENCAPSULATION PROCESS
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
HU222501B1 (en) * 1991-06-28 2003-07-28 Endorecherche Inc. Controlled release pharmaceutical composition containing mpa or mga and process for its preparation
KR100333115B1 (en) * 1992-11-17 2002-12-02 미츠비시 파마 코포레이션 Sustained-release microsphere containing antipsychotic and process for producing the same
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
KR100354270B1 (en) * 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazole and 1,2-benzisothiazole
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process

Also Published As

Publication number Publication date
CN1226821A (en) 1999-08-25
US5916598A (en) 1999-06-29
IL126509A (en) 2004-08-31
US20050276859A1 (en) 2005-12-15
NO984808D0 (en) 1998-10-15
PL329720A1 (en) 1999-04-12
PL188550B1 (en) 2005-02-28
AU733199B2 (en) 2001-05-10
EE9800383A (en) 1999-04-15
UA59361C2 (en) 2003-09-15
WO1997041837A3 (en) 1998-02-26
RU2201214C2 (en) 2003-03-27
EE04540B1 (en) 2005-10-17
US20040197417A1 (en) 2004-10-07
EP0904063B1 (en) 2002-09-04
NO323591B1 (en) 2007-06-11
JP3822909B2 (en) 2006-09-20
CN1224380C (en) 2005-10-26
JP4769119B2 (en) 2011-09-07
NO984808L (en) 1999-01-06
CZ293578B6 (en) 2004-06-16
BG64036B1 (en) 2003-11-28
IL126509A0 (en) 1999-08-17
US20030129249A1 (en) 2003-07-10
US5792477A (en) 1998-08-11
NZ333196A (en) 2000-02-28
KR20000010697A (en) 2000-02-25
CA2251987C (en) 2005-05-10
EP0904063A2 (en) 1999-03-31
US20020146457A1 (en) 2002-10-10
ZA973891B (en) 1997-11-07
NO20065995L (en) 1999-01-06
ID17505A (en) 1998-01-08
HU223532B1 (en) 2004-08-30
US6110503A (en) 2000-08-29
CZ359198A3 (en) 1999-03-17
WO1997041837A2 (en) 1997-11-13
HUP9902797A3 (en) 2001-09-28
US20020028249A1 (en) 2002-03-07
JP2000503663A (en) 2000-03-28
SK154198A3 (en) 1999-05-07
US6403114B1 (en) 2002-06-11
BR9709217A (en) 1999-08-10
HUP9902797A2 (en) 1999-12-28
AR046034A2 (en) 2005-11-23
AR012820A1 (en) 2000-11-22
JP2006249440A (en) 2006-09-21
BG102854A (en) 1999-05-31
SK283852B6 (en) 2004-03-02
US6290983B1 (en) 2001-09-18
KR100432677B1 (en) 2004-09-13
AU2897297A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
CA2251987A1 (en) Microparticles
MY118174A (en) Process for the preparation of microparticles
EP1142567A3 (en) Production of microspheres
CA2219698A1 (en) Sustained-release preparation
WO2000049084A8 (en) Hyaluronic acid gel composition, process for producing the same, and medical material containing the same
CA2320900A1 (en) Biphasic controlled release delivery system for high solubility pharmaceuticals and method
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
AU7143796A (en) Controlled release matrix for pharmaceuticals
AU589841B2 (en) Skin treatment composition
ES2195173T3 (en) PROCEDURE FOR THE POLYMERIZATION OF ALFA-OLEFINS, CATALYST USED IN THE POLYMERIZATION AND ITS PREPARATION.
CA2171303A1 (en) Active principles and gas containing microparticles
EP0338732A3 (en) Matrix for release of active ingredients
CA2321461A1 (en) Cross-linked high amylose starch having functional groups as a matrix for the slow release of pharmaceutical agents
EP0614922A3 (en) Process for the preparation of an aqueous polymer dispersion.
KR20000005337A (en) Controlled-release pharmaceutical tablet containing a carrier based on cross-linked amylose and hydromypropylmethylcellul-ose
CA2170748A1 (en) Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
AU6947801A (en) Hyaluronic acid oligosaccharide fractions and drugs containing the same
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
CA2283876A1 (en) Delivery systems
EP1842544A3 (en) Alginate compositions
TW327602B (en) A pharmaceutical composition of an ophthalmic suspension containing difluprednate
CA2375931A1 (en) Tissue products having antiviral properties
AUPN991796A0 (en) Early detection of lysosomal storage disorders
ZA967288B (en) Products and processes for the sustained release of agricultural active ingredients.
IL139576A0 (en) Biologically active composition

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170510